Tumor Necrosis Factor Inhibitors in Psoriasis: An Update

Highlights of the Skin Disease Education Foundation 10th Annual Psoriasis Forum

Tumor Necrosis Factor Inhibitors in Psoriasis: An Update

Mar
2014
Vol. 33. No. 2
Bruce E. Strober, MD, PhD | Francisco A Kerdel, BSc, MBBS

Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.

VIEW FULL ARTICLE PDF